Clinical Trials Logo

Clinical Trial Summary

The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04752371
Study type Interventional
Source Apollo Therapeutics Ltd
Contact
Status Terminated
Phase Phase 1
Start date March 25, 2021
Completion date May 24, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04717635 - Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD Phase 3